Phase 2 N=174 Association Between Body Size and Response to Hydromorphone in ED
Pain
Primary: Correlation Between Change in Pain Intensity and TBW at 30 Minutes Post-treatment — -0.03 correlation coefficient
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=8 D-serine and Cognitive Remediation in Schizophrenia
Schizophrenia
Primary: Mismatch Negativity (MMN) — .086; 0.31 micro volts
Phase 2 N=121 Dose-response Relationship Study of S42909 on Leg Ulcer Healing
Venous Leg Ulcer
Primary: Relative Reduction of Reference Ulcer Area After 4 Weeks of Treatment on Top of Standard of Care Compared With Baseline Reference Ulcer Area (W000) Assessed During Study…
Phase 2 N=317 Selinexor (KPT-330) in Older Patients With Relapsed AML
Acute Myeloid Leukemia (AML)
Primary: Overall Survival — 94.0; 170.0 Days — p=0.4221
Phase 2 N=24 Effect of Ursolic Acid Administration on Insulin Sensitivity and Metabolic Syndrome
Metabolic Syndrome X
Primary: Total Insulin Sensitivity — 4.2; 2.6 index — p=0.003
Phase 2 N=24 Efficacy of Steroid Supplementation After TMJ Rinsing for Pain Management
Pain
Primary: Change From Pre-Treatment in TMJ Loading Pain Rating at 12 Weeks — -1; -2 units on a scale
Phase 2 N=42 Single Arm on the Tolerability of Weekly Nab-paclitaxel
Non Small Cell Lung Cancer (NSCLC)
Primary: Number of Subjects Without Any Adverse Events Grade 3 or Higher — 28 Participants
Phase 2 N=246 Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy
Geographic Atrophy
Primary: Least Square (LS) Mean Change From Baseline in Square Root GA Lesion Size in the Study Eye at Month 12 — 0.26; 0.28; 0.35 mm
Phase 2 N=69 Cabozantinib for Advanced Urothelial Cancer
Urothelial Carcinoma · Urethral Neoplasms · Urinary Bladder Neoplasms
Primary: Percentage of Participants With Overall Response — 19.1; NA; NA percentage of participants
Phase 2 N=21 Early Phase Study to Assess Efficacy and Safety of AZD9567 Versus Prednisolone in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Least Square (LS) Mean Change From Baseline in 28 Joint Disease Activity Score Using C-Reactive Protein (DAS28-CRP) at Day 15 — -1.931; -2.403 score on a scale — p=0.315
Phase 2 N=77 A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)
Atopic Dermatitis
Primary: Pharmacokinetics (PK) of Dupilumab: Maximum Plasma Concentration Observed (Cmax) After Single Administration — 9.91; 14.3; 23.1; 32.4 mg/L
Phase 2 N=55 Safety and Effectiveness of D-serine in Schizophrenia
Schizophrenia
Primary: Renal Safety Measures — 0; 0; 1 adverse events
Phase 2 N=24 Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
Locally Advanced Basal Cell Carcinoma · Skin Cancer · Cutaneous Malignancy
Primary: Percentage of Patients With Local-regional Control Rate — 100 percentage
Phase 2 N=65 Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A
Influenza A H3N2 · Influenza A H1N1
Primary: Frequency Counts and Percentage of Subjects With Adverse Events — 6; 6; 1; 3 Participants
Phase 2 N=63 Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas
Primary: Number of Subjects With an Overall Response (i.e. Either Complete Response or Partial Response) Evaluated at Three Months Post Infusion. — 24; 1; 1 Participants